Evidence map›Paper›PMID 21719620›Full record

ArticleMayo Clinic proceedings2011

The science and ethics of induced pluripotency: what will become of embryonic stem cells?

David G Zacharias, Timothy J Nelson, Paul S Mueller, C Christopher Hook

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Highlights on Advancing Frontiers in Tissue Engineering.Tissue engineering. Part B, Reviews · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

David G ZachariasMayo Medical School, Mayo Clinic, Rochester, MN 55905, USA.
Timothy J Nelson
Paul S Mueller
C Christopher Hook

Funding

Dysfunctional regeneration in cardiomyopathy: iPS-based diagnosis and therapyDP2OD007015 · OD · MAYO CLINIC ROCHESTER · PI NELSON, TIMOTHY JAMES · 2010 to 2010
$2.4M
NIH HHS 1DP2OD007015NIH HHS DP2 OD007015
6 · The paper itself

Abstract

For over a decade, the field of stem cell research has advanced tremendously and gained new attention in light of novel insights and emerging developments for regenerative medicine. Invariably, multiple considerations come into play, and clinicians and researchers must weigh the benefits of certain stem cell platforms against the costs they incur. Notably, human embryonic stem (hES) cell research has been a source of continued debate, leading to differing policies and regulations worldwide. This article briefly reviews current stem cell platforms, looking specifically at the two existing pluripotent lines available for potential therapeutic applications: hES cells and induced pluripotent stem (iPS) cells. We submit iPS technology as a viable and possibly superior alternative for future medical and research endeavors as it obviates many ethical and resource-related concerns posed by hES cells while prospectively matching their potential for scientific use. However, while the clinical realities of iPS cells appear promising, we must recognize the current limitations of this technology, avoid hype, and articulate ethically acceptable medical and scientific goals.

Indexed as

Embryonic Stem CellsPluripotent Stem CellsHumansRegenerative Medicine

Identifiers

PMID21719620
PMCPMC3127559

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.